Early HBcrAg and Anti‐ HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation—A Pooled Analysis of Two Clinical Trials
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.18416 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Edo J Dongelmans und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B Core Antigens. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Stichting voor Lever- en Maag-Darm Onderzoek.
Abstract (Originalsprache)
Background
Severe flares (ALT ≥ 10×ULN) are a well‐recognised adverse outcome after nucleos(t)ide analogue (NA) cessation and may lead to liver failure. Thus, identification of patients at risk for these flares is of major importance.
Methods
Data were used from two prospective studies on NA cessation conducted in the Netherlands and Canada. Patients were eligible based on EASL criteria. HBcrAg and anti‐HBc levels were measured at end of treatment (EOT) and week 6 (FUW6). Logistic regression was used to study the association with severe flares.
Results
Seventy‐eight patients were analysed with a mean age of 49 years, 16 (21%) Caucasian and a majority (65%) were treated with Tenofovir. Overall, 22 patients (28%) developed a severe flare, and 29 (37%) patients were retreated. At EOT, higher HBcrAg levels (aOR: 1.97, p = 0.05; ≥ 4log: 47% severe flare vs. < 3log: 19%, p = 0.036), lower anti‐HBc (aOR: 0.29, p = 0.036; < 2log: 50% vs. ≥ 3log: 11%, p = 0.029) and higher HBcrAg/anti‐HBc‐ratio (aOR: 3.17, p = 0.015; ≥ 2: 58% vs. < 1.5: 14%, p < 0.001) were associated with an increased risk of severe flares, adjusted for HBsAg. At FUW6, higher HBcrAg (aOR: 2.91, p = 0.035; ≥ 5log: 83%, < 3log: 4%, p < 0.001), lower anti‐HBc (aOR: 0.46, p = 0.29; < 2log: 50% vs. ≥ 3log: 0%, p = 0.003) and higher HBcrAg/anti‐HBc‐ratio (aOR: 2.19, p = 0.048; ≥ 1.75: 52% vs. < 1.75: 8%, p < 0.001) were associated with an increased risk of severe flares, adjusted for HBV DNA and ALT.
Conclusion
Higher HBcrAg, lower anti‐HBc and higher HBcrAg/anti‐HBc ratio at EOT and during the first weeks of post‐treatment follow‐up are associated with an increased risk of hepatic flares after NA withdrawal and could therefore potentially be used to select patients eligible for therapy cessation and to identify patients requiring retreatment. Trial Registration: This study was a post hoc and follow‐up study of two previously registered clinical trials (NCT01911156 & NTR7001). No new patients were prospectively included
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
- Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto, ON, Canada.
- The Toronto Viral Hepatitis Care Network (VIRCAN), Toronto, ON, Canada.
- Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
- Department of Gastroenterology and Hepatology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
- Department of Epidemiology and Biostatistics, Erasmus University Medical Centre, Rotterdam, The Netherlands.
ORCID-Profile: Edo J Dongelmans, Sylvia M Brakenhoff, Scott Fung, Florian van Bömmel, Milan J Sonneveld
Förderung
- Stichting voor Lever- en Maag-Darm Onderzoek
Zitieren
APA
Dongelmans, E. J., Feld, J. J., Boonstra, A., Brakenhoff, S. M., Wong, D., Yim, C., Claassen, M., Honkoop, P., Hansen, B. E., de Man, R. A., Fung, S., Berg, T., van Bömmel, F., Janssen, H. L. A., & Sonneveld, M. J. (2025). Early HBcrAg and Anti‐ HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation—A Pooled Analysis of Two Clinical Trials. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18416
Vancouver
Dongelmans EJ, Feld JJ, Boonstra A, Brakenhoff SM, Wong D, Yim C, et al. Early HBcrAg and Anti‐ HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation—A Pooled Analysis of Two Clinical Trials. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18416
BibTeX
@article{Dongelmans2025,
author = {Dongelmans, Edo J and Feld, Jordan J and Boonstra, André and Brakenhoff, Sylvia M and Wong, David and Yim, Colina and Claassen, Mark and Honkoop, Pieter and Hansen, Bettina E and de Man, Robert A and Fung, Scott and Berg, Thomas and van Bömmel, Florian and Janssen, Harry L A and Sonneveld, Milan J},
title = {Early HBcrAg and Anti‐ HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation—A Pooled Analysis of Two Clinical Trials},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.18416}
}
EUVIMED